Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; this is a minor maintenance update with no visible changes to study data or navigation, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedUI text updates include glossary toggle options ('Show glossary' and 'Hide glossary') and capitalization tweaks to QC-related labels (e.g., No FEAR Act Data). The page revision was updated to v3.4.0.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. This is a routine version label change.SummaryDifference0.0%

- Check69 days agoChange DetectedA centralized Locations section was added, enumerating study sites across many countries, and several regional location blocks were removed.SummaryDifference2%

- Check91 days agoChange DetectedPublication section wording updated to clarify auto-population from PubMed and potential non-relations to the study. Page revision tag updated to Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.